Home » Authors » James Etheridge

Articles by James Etheridge

Aptanomics Raises EUR7M For Peptide Aptamer-Based Platform

Nov. 6, 2002

By James Etheridge

Avidis Closing EUR1.7M Round To Develop Peptides Technology

Nov. 6, 2002

By James Etheridge

Aptanomics Raises EUR7M For Peptide Aptamer-Based Platform

Nov. 6, 2002

By James Etheridge

Genome Express Unveils New Gene Discovery Technology

Oct. 30, 2002

By James Etheridge

IDM Enters Research Agreement With Nemod On Immunotherapies

Oct. 30, 2002

By James Etheridge

Genset Delists From Nasdaq, Closes Paris Headquarters

Oct. 30, 2002

By James Etheridge

ExonHit Initiates Clinical Trial Of Lead Compound For ALS

Oct. 30, 2002

By James Etheridge

ExonHit Initiates Clinical Trial Of Lead Compound For ALS

Oct. 30, 2002

By James Etheridge

Genome Express Unveils New Gene Discovery Technology

Oct. 30, 2002

By James Etheridge

Genset Delists From Nasdaq, Closes Paris Headquarters

Oct. 30, 2002

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 13, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 13, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...
Keros stock wilts as it halts two dosing arms in hypertension study
BioWorld
After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.